C4279981||genome-edited
C4039583||chimeric antigen receptor
C0039194||T cell
C0087111||therapeutic
C3658200||CRISPR
C0278348||cancer immunotherapy
C4277689||genetically modified
C0034790||T cell receptor
C4039583||chimeric antigen receptor
C4039583||chimeric antigen receptor
C0039194||T cells
C0017428||genomic
C0678933||gene loci
C0007634||donor cells
C3641722||effector T cells
C1418401||PD-1
C1332802||CTLA4
C0302189||cell therapy
C2603343||study
C4279981||genomic editing
C0039194||T cells
C0456981||antigen specific
C4039583||chimeric antigen receptor
C3658200||CRISPR
C0442711||protocol
C0082774||gRNAs
C4039583||chimeric antigen receptor
C1520007||lentiviral vector
C0599772||knockout
C0034790||TCR
C0008897||HLA class I
C4039583||chimeric antigen receptor
C0039194||T cells
C1454645||Fas
C4039583||chimeric antigen receptor
C0039194||T cells
C0017337||gene
C4277689||gene editing
C0678933||gene loci
C3658200||CRISPR
C0442711||protocol
C0039194||T cells
C1418401||PD1
C1332802||CTLA-4